Meropenem population pharmacokinetics in critically Ill patients with septic shock and continuous renal replacement therapy: Influence of residual diuresis on dose requirements

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 9, 2015, Pages 5520-5528

  Ulldemolins, Marta ^a,b,c   Soy, Dolors ^a,c,d,e,f   Llaurado Serra, Mireia ^g,h   Vaquer, Sergi ^b   Castro, Pedro ^c,d,f   Rodríguez, Alejandro H ^e,h   Pontes, Caridad ^b,i   Calvo, Gonzalo ^c,d,f   Torres, Antoni ^a,c,d,e,f   Martín Loeches, Ignacio ^b,e,j  

^a Fundació Privada Clinic per A la Recerca Biomèdica   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

^d HOSPITAL CLÍNIC   (Spain)

^e INSTITUTO DE SALUD CARLOS III   (Spain)

^f INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^g UNIVERSITAT ROVIRA I VIRGILI   (Spain)

^h HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

ⁱ PARC TAULÍ HOSPITAL UNIVERSITARI   (Spain)

^j ST JAMES S HOSPITAL   (Ireland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

MEROPENEM; ANTIINFECTIVE AGENT; THIENAMYCIN DERIVATIVE;

ADULT; AGED; APACHE; ARTICLE; CLINICAL ARTICLE; CONTINUOUS RENAL REPLACEMENT THERAPY; CRITICALLY ILL PATIENT; DIURESIS; FEMALE; HUMAN; MALE; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; PHARMACOKINETICS; PRIORITY JOURNAL; RESIDUAL DIURESIS; SEPTIC SHOCK; UNBOUND FRACTION; VOLUME OF DISTRIBUTION; CRITICAL ILLNESS; METABOLISM; MICROBIAL SENSITIVITY TEST; MIDDLE AGED; PROSPECTIVE STUDY; RENAL REPLACEMENT THERAPY; SHOCK, SEPTIC; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CRITICAL ILLNESS; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL REPLACEMENT THERAPY; SHOCK, SEPTIC; THIENAMYCINS;

EID: 84940920669     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00712-15     Document Type: Article

References (45)

1. Agencia Española de Medicamentos y Productos Sanitarios. 2015. Meropenem product information. Agencia Española de Medicamentos y Productos Sanitarios, Madrid, Spain. http://www.aemps.gob.es/medicamentosUsoHumano/portada/home.htm. Accessed April 2015.
2. Rello J, Ulldemolins M, Lisboa T., Koulenti D, Manez R, Martin-Loeches I, De Waele JJ, Putensen C, Guven M, Deja M., Diaz E, Group E-VCS. 2011. Determinants of prescription and choice of empirical therapy for hospital-acquired and ventilator-associated pneumonia. Eur Respir J 37:1332-1339. http://dx.doi.org/10.1183/09031936.00093010.
3. Craig WA. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 26:1-10. http://dx.doi.org/10.1086/516284.
4. Roberts JA, Paul SK, Akova M, Bassetti M., De Waele JJ, Dimopoulos G, Kaukonen KM, Koulenti D, Martin C., Montravers P, Rello J, Rhodes A., Starr T, Wallis SC, Lipman J, DALI Study. 2014. DALI: defining antibiotic levels in intensive care unit patients: are current beta-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis 58:1072-1083. http://dx.doi.org/10.1093/cid/ciu027.
5. Li C, Du X, Kuti J.L., Nicolau DP. 2007. Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections. Antimicrob Agents Chemother 51:1725-1730. http://dx.doi.org/10.1128/AAC.00294-06.
6. Ulldemolins M, Vaquer S, Llaurado-Serra M, Pontes C., Calvo G, Soy D, Martin-Loeches I. 2014. Beta-lactam dosing in critically ill patients with septic shock and continuous renal replacement therapy. Crit Care 18:227. http://dx.doi.org/10.1186/cc13938.
7. Heintz BH, Matzke GR, Dager WE 2009. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. Pharmacotherapy 29:562-577. http://dx.doi.org/10.1592/phco.29.5.562.
8. Krueger WA, Schroeder TH, Hutchison M, Hoffmann E., Dieterich HJ, Heininger A, Erley C, Wehrle A., Unertl K. 1998. Pharmacokinetics of meropenem in critically ill patients with acute renal failure treated by continuous hemodiafiltration. Antimicrob Agents Chemother 42:2421-2424.
9. Krueger WA, Neeser G, Schuster H., Schroeder TH, Hoffmann E, Heininger A, Dieterich H.J., Forst H., Unertl KE. 2003. Correlation of meropenem plasma levels with pharmacodynamic requirements in critically ill patients receiving continuous veno-venous hemofiltration. Chemotherapy 49:280-286. http://dx.doi.org/10.1159/000074527.
10. Thalhammer F, Schenk P, Burgmann H., El Menyawi I, Hollenstein UM, Rosenkranz A.R., Sunder-Plassmann G, Breyer S, Ratheiser K. 1998. Single-dose pharmacokinetics of meropenem during continuous venovenous hemofiltration. Antimicrob Agents Chemother 42:2417-2420.
11. Tegeder I, Neumann F, Bremer F., Brune K, Lotsch J, Geisslinger G. 1999. Pharmacokinetics of meropenem in critically ill patients with acute renal failure undergoing continuous venovenous hemofiltration. Clin Pharmacol Ther 65:50-57. http://dx.doi.org/10.1016/S0009-9236(99)70121-9.
12. Valtonen M, Tiula E, Backman J.T., Neuvonen PJ. 2000. Elimination of meropenem during continuous veno-venous haemofiltration and haemo-diafiltration in patients with acute renal failure. J Antimicrob Chemother 45:701-704. http://dx.doi.org/10.1093/jac/45.5.701.
13. Robatel C, Decosterd LA, Biollaz J, Eckert P., Schaller MD, Buclin T. 2003. Pharmacokinetics and dosage adaptation of meropenem during continuous venovenous hemodiafiltration in critically ill patients. J Clin Pharmacol 43:1329-1340. http://dx.doi.org/10.1177/0091270003260286.
14. Langgartner J, Vasold A, Gluck T., Reng M, Kees F. 2008. Pharmacokinetics of meropenem during intermittent and continuous intravenous application in patients treated by continuous renal replacement therapy. Intensive Care Med 34:1091-1096. http://dx.doi.org/10.1007/s00134-008-1034-7.
15. Seyler L, Cotton F, Taccone F.S., De Backer D, Macours P, Vincent J.L., Jacobs F. 2011. Recommended beta-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy. Crit Care 15:R137. http://dx.doi.org/10.1186/cc10257.
16. Isla A, Rodriguez-Gascon A, Troconiz I.F., Bueno L., Solinis MA, Maynar J, Sanchez-Izquierdo JA, Pedraz JL. 2008. Population pharmacokinetics of meropenem in critically ill patients undergoing continuous renal replacement therapy. Clin Pharmacokinet 47:173-180. http://dx.doi.org/10.2165/00003088-200847030-00003.
17. Isla A, Maynar J, Sanchez-Izquierdo JA, Gascon A.R., Arzuaga A., Corral E, Pedraz JL. 2005. Meropenem and continuous renal replacement therapy: in vitro permeability of 2 continuous renal replacement therapy membranes and influence of patient renal function on the pharmacokinetics in critically ill patients. J Clin Pharmacol 45:1294-1304. http://dx.doi.org/10.1177/0091270005280583.
18. Varghese JM, Jarrett P, Wallis S.C., Boots RJ, Kirkpatrick CM, Lipman J, Roberts JA 2015. Are interstitial fluid concentrations of meropenem equivalent to plasma concentrations in critically ill patients receiving continuous renal replacement therapy? J Antimicrob Chemother 70:528-533. http://dx.doi.org/10.1093/jac/dku413.
19. Giles LJ, Jennings AC, Thomson A.H., Creed G., Beale RJ, McLuckie A. 2000. Pharmacokinetics of meropenem in intensive care unit patients receiving continuous veno-venous hemofiltration or hemodiafiltration. Crit Care Med 28:632-637. http://dx.doi.org/10.1097/00003246-200003000-00005.
20. Dellinger RP, Levy MM, Rhodes A, Annane D., Gerlach H, Opal SM, Sevransky J.E., Sprung CL, Douglas IS, Jaeschke R, Osborn T.M., Nunnally ME, Townsend SR, Reinhart K, Kleinpell R.M., Angus DC, Deutschman CS, Machado FR, Rubenfeld G.D., Webb SA, Beale RJ, Vincent JL, Moreno R, Surviving Sepsis Campaign Guidelines Committee including the Pediatric Subgroup. 2013. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 41:580-637. http://dx.doi.org/10.1097/CCM.0b013e31827e83af.
21. Knaus WA, Draper EA, Wagner D.P., Zimmerman JE. 1985. APACHE II: a severityofdisease classification system. Crit Care Med 13:818-829. http://dx.doi.org/10.1097/00003246-198510000-00009.
22. Vincent JL, Moreno R, Takala J., Willatts S, De Mendonca A, Bruining H, Reinhart C.K., Suter PM, Thijs LG. 1996. The SOFA (sepsis-related organ failure assessment) score to describe organ dysfunction/failure. On behalf of the Working Groupon Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 22:707-710.
23. Li AM, Gomersall CD, Choi G, Tian Q., Joynt GM, Lipman J. 2009. A systematic review of antibiotic dosing regimens for septic patients receiving continuous renal replacement therapy: do current studies supply sufficient data? J Antimicrob Chemother 64:929-937. http://dx.doi.org/10.1093/jac/dkp302.
24. European Medicines Agency. 2014. Guideline on bioanalytical method validation. European Medicines Agency, London, United Kingdom. http://www.ema.europa.eu. Accessed August 2014.
25. Beal S, Sheiner LB, Boeckmann A, Bauer RJ 2009. NONMEM user's guides (1989-2009). Icon Development Solutions, Ellicott City, MD.
26. Jonsson EN, Karlsson MO 1999. Xpose - an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 58:51-64.
27. Sheiner LB, Steimer JL 2000. Pharmacokinetic/pharmacodynamic modeling in drug development. Annu Rev Pharmacol Toxicol 40:67-95. http://dx.doi.org/10.1146/annurev.pharmtox.40.1.67.
28. Sheiner L, Wakefield J. 1999. Population modelling in drug development. Stat Methods Med Res 8:183-193. http://dx.doi.org/10.1191/096228099672920676.
29. Ette EI, Ludden TM 1995. Population pharmacokinetic modeling: the importance of informative graphics. Pharm Res 12:1845-1855. http://dx.doi.org/10.1023/A:1016215116835.
30. Hooker AC, Staatz CE, Karlsson MO 2007. Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method. Pharm Res 24:2187-2197. http://dx.doi.org/10.1007/s11095-007-9361-x.
31. Savic RM, Karlsson MO 2009. Importance of shrinkage in empirical Bayes estimates for diagnostics: problems and solutions. AAPS J 11:558-569. http://dx.doi.org/10.1208/s12248-009-9133-0.
32. Bergstrand M, Hooker AC, Wallin J.E., Karlsson MO. 2011. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J 13:143-151. http://dx.doi.org/10.1208/s12248-011-9255-z.
33. Efron B. 1979. Bootstrap methods: another look at the jackknife. Ann Stat 7:1-26. http://dx.doi.org/10.1214/aos/1176344552.
34. Ette EI, Williams PJ, Kim Y.H., Lane JR, Liu MJ, Capparelli EV. 2003. Model appropriateness and population pharmacokinetic modeling. JClin Pharmacol 43:610-623. http://dx.doi.org/10.1177/0091270003253624.
35. Ette EI. 1997. Stability and performance of a population pharmacokinetic model. J Clin Pharmacol 37:486-495. http://dx.doi.org/10.1002/j.1552-4604.1997.tb04326.x.
36. Food and Drug Administration. 1999. Guidance for industry. Population pharmacokinetics. Food and Drug Administration, Rockville, MD. http://www.fda.gov/downloads/Drugs/Guidances/UCM072137.pdf. Accessed December 2014.
37. Sheiner LB, Beal SL 1981. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 9:503-512. http://dx.doi.org/10.1007/BF01060893.
38. Rozman C, Cardellach F (ed). 2012. Farreras-Rozman medicina interna, 17th ed. Elsevier, Barcelona, Spain.
39. European Committee on Antimicrobial Susceptibility Testing. April 2015. Clinical breakpoints. http://www.eucast.org.
40. Mouton JW, Brown DF, Apfalter P, Canton R., Giske CG, Ivanova M, MacGowan AP, Rodloff A, Soussy C.J., Steinbakk M., Kahlmeter G. 2012. The role of pharmacokinetics/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach. Clin Microbiol Infect 18:E37-E45. http://dx.doi.org/10.1111/j.1469-0691.2011.03752.x.
41. Jamal JA, Udy AA, Lipman J, Roberts JA 2014. The impact of variation in renal replacement therapy settings on piperacillin, meropenem, and vancomycin drug clearance in the critically ill: an analysis of published literature and dosing regimens. Crit Care Med 42:1640-1650. http://dx.doi.org/10.1097/CCM.0000000000000317.
42. Roberts DM, Liu X, Roberts J.A., Nair P., Cole L, Roberts MS, Lipman J, Bellomo R., RENAL Replacement Therapy Study Investigators. 2015. A multicenter study on the effect of continuous hemodiafiltration intensity on antibiotic pharmacokinetics. Crit Care 19:818. http://dx.doi.org/10.1186/s13054-015-0818-8.
43. Honore PM, Jacobs R, Lochy S., De Waele E, Van Gorp V, De Regt J, Martens G, Joannes-Boyau O, Boer W., Spapen HD. 2013. Acute respiratory muscle weakness and apnea in a critically ill patient induced by colistin neurotoxicity: key potential role of hemoadsorption elimination during continuous venovenous hemofiltration. Int J Nephrol Renovasc Dis 6:107-111. http://dx.doi.org/10.2147/IJNRD.S42791.
44. Brendel K, Dartois C, Comets E., Lemenuel-Diot A, Laveille C, Tranchand B., Girard P, Laffont CM, Mentre F. 2007. Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004. Clin Pharmacokinet 46:221-234.
45. Meyer MM, Munar MY, Kohlhepp S.J., Bryant RE. 1999. Meropenem pharmacokinetics in a patient with multiorgan failure from meningococcemia undergoing continuous venovenous hemodiafiltration. Am J Kidney Dis 33:790-795. http://dx.doi.org/10.1016/S0272-6386(99)70236-2.